Nearly one in five young adults now vapes, according to Gallup's August survey, which found 9 percent of U.S. adults overall use e-cigarettes. Nicotine pouches also skew young. This marks a generational shift in habits that progressives must confront—and a voting bloc worth courting.
Svante Myrick, president of People For the American Way and former mayor of Ithaca, New York, draws on his city's opioid crisis to make the case. In 2014, three people died of heroin overdoses in Ithaca within ten days. "We watched people die while America argued about whether harm reduction somehow condoned drug use," he recalls. In response, Ithaca developed a comprehensive plan uniting prevention, treatment, law enforcement, and harm reduction—even exploring supervised injection sites.
His lesson: "Condemnation is not a substitute for sensible policy. Moral judgment is not a substitute for evidence." That principle applies to tobacco, where the evidence has shifted. The Food and Drug Administration maintains that no tobacco product is safe but acknowledges a continuum of risk: cigarettes are most harmful, while non-combusted products like e-cigarettes and nicotine pouches generally pose lower risks. In June, the FDA authorized 20 Zyn nicotine pouches to carry modified-risk claims, stating they lower the risk of several smoking-related diseases compared to cigarettes.
Vaping's evidence base is also strengthening. A July JAMA commentary by University of Massachusetts assistant professor Jamie Hartmann-Boyce noted that nicotine e-cigarettes are more effective for smoking cessation than FDA-approved nicotine replacement therapies. A companion paper recommended integrating e-cigarettes into clinical conversations with adult smokers.
None of this makes vaping harmless. Nicotine is addictive, minors should not use it, and long-term effects need study. But "not harmless" is not the same as "as harmful as cigarettes."
For policymakers, this creates a regulatory agenda: age verification, manufacturing standards, ingredient disclosure, restrictions on youth marketing, and an FDA system that distinguishes regulated products from illicit ones. Generational shifts in politics add urgency.
Vaping is most prevalent among Americans under 30, and Pew finds that age group prefers Democratic congressional candidates by 47 to 24 percent. These statistics overlap; they don't prove tobacco policy decides votes. But they show millions of young, Democratic-leaning voters use these products. Trust across generations is already fragile; dismissing their choices could deepen the divide.
Myrick argues that shame doesn't erase addiction, and pretending people will stop because government wishes it won't work. "Good public policy begins with the world as it actually exists," he says, "and reaching out a supportive hand instead of a wagging finger." Democrats, he suggests, can run on these issues as a caring, nonjudgmental party—"more like cool parents and less like the worst members of a homeowners' association board."
As the party faces internal generational tensions, embracing evidence-based tobacco regulation could be a smart political move. It aligns with harm reduction principles and could resonate with young voters who see vaping as part of their daily lives. The question is whether Democrats will seize it or cede the ground to moralizing.
